Clinical Trials Logo

Clinical Trial Summary

Based on our research background, we hypothesize that LIFUS has neuromodulation effects on brain cortex and the active LIFUS on left-DLPFC would improve negative symptoms in schizophrenia patients. It would firstly verify the safety of LIFUS on human as well. The multimodal MRI will be contributed to investigate the possible mechanism of negative symptoms.


Clinical Trial Description

Firstly, we plan to explore the short-term effects of LIFUS on cortical excitability by detecting the MEP amplitude. 40 patients and relatively well matched healthy-control would be enrolled. After MEP detection and baseline evaluations, the two groups will be treated with one-single intervention on the primary motor cortex. The cognitive function and MEP amplitude will be assessed respectively at the moment, after 15 minutes and 30 minutes. Then, it is a randomized double-blind sham-controlled LIFUS intervention trial in schizophrenia patients. After screening and baseline evaluations, the 40 patients with schizophrenia will be treated with active LIFUS or sham stimulation for 3 weeks on the left DLPFC. The multimodal MRI will be acquired. Clinical symptoms and cognitive function will be assessed respectively at baseline, at the end of fifth treatments and after the end of the treatment. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT04620460
Study type Interventional
Source Shanghai Mental Health Center
Contact Dengtang LIU
Phone 18017311138
Email erliu110@126.com
Status Recruiting
Phase N/A
Start date August 5, 2020
Completion date July 31, 2022

See also
  Status Clinical Trial Phase
Not yet recruiting NCT05985993 - Precise Intervention Technology and Application of Low Intensity TUS on Negative Symptoms of Schizophrenia N/A
Not yet recruiting NCT06388551 - A Phase 1, SAD Study to Evaluate the Safety and Tolerability of LY03017 Phase 1
Withdrawn NCT01234298 - SPD489 as Adjunctive Treatment in Adults With Negative Symptoms of Schizophrenia Phase 3
Completed NCT03397134 - Study to Evaluate Efficacy and Safety of Roluperidone (MIN-101) in Adult Patients With Negative Symptoms of Schizophrenia Phase 3